IMREG's TREATMENT IND REQUEST FOR ANTI-AIDS DRUG IMREG-1
IMREG's TREATMENT IND REQUEST FOR ANTI-AIDS DRUG IMREG-1 is expected to be reviewed by FDA's Vaccines and Related Biologicals Advisory Committee at a meeting tentatively scheduled for April 7. The April meeting will be the second opportunity for the advisory committee to review Imreg's Treatment IND application. The committee heard contradictory presentations from FDA and the company at a Nov. 18 meeting. The agency presentations indicated that the Imreg data fail to provide evidence of the efficacy of Imreg-1 in preventing AIDS-related complex from progressing to AIDS. At the request of Imreg, the committee deferred making a recommendation on the application so that the firm could evaluate and respond to FDA's analyses of the data ("The Pink Sheet" Nov. 21, p. 3). The company recently received a complete set of FDA's analyses and presumably has prepared counterarguments for review by the advisory committee. FDA advisory committees do not usually defer recommendations to allow drug sponsors to prepare rebuttals. However, the November meeting was the first in which an advisory committee was asked to consider a Treatment IND application. FDA was under the Treatment IND regulation's 30-day time deadline to approve or disapprove the request; consequently, it had sent the committee an information package only a few days in advance of the meeting. The committee acknowledged at the meeting that it felt unprepared to render a formal recommendation. Since then, on Nov. 22, FDA placed a clinical hold on the Treatment IND protocol and eliminated the regulatory time constraint ("The Pink Sheet" Dec. 5, T&G-5). In January, Center for Biologics Evaluation and Research Director Paul Parkman, MD, reportedly sent Imreg President Arthur Gottlieb, MD, a three-page letter detailing the reasons why FDA had concluded that the company's data do not demonstrate the efficacy of Imreg-1. The agency has said its concerns with the application include the manufacture, characterization, and consistency of the product and the design and execution of the clinical trial.(ITEM 200)#050928M001J59307# #970804M001XFCWP5# (ITEM 201)(COPYRIGHT) 1989 F-D-C Reports, Inc., The Pink Sheet, February 20, 1989
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth